Trial Profile

INFORM2 Exploratory Multinational Phase I/II Combination Study of Nivolumab and Entinostat in Children and Adolescents With Refractory High-risk Malignancies (INFORM2-NivEnt)

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 12 Feb 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Entinostat (Primary) ; Nivolumab (Primary)
Indications Bone cancer; CNS cancer; Ependymoma; Germ cell and embryonal neoplasms; Glioma; Medulloblastoma; Neuroblastoma; Renal cell carcinoma; Rhabdoid tumour; Rhabdomyosarcoma; Sarcoma; Solid tumours; Wilms' tumour
Focus Adverse reactions; Therapeutic Use
Acronyms INFORM2; INFORM2 NivEnt

Most Recent Events

05 Feb 2024 Planned End Date changed from 30 Jun 2025 to 30 Jun 2027.
05 Feb 2024 Planned End Date changed from 30 Jun 2025 to 30 Jun 2027.
05 Feb 2024 Planned primary completion date changed from 30 Jun 2024 to 30 Jun 2026.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com